CANBRIDGE PHARM.DL-00001 (MF1) - Total Assets
Based on the latest financial reports, CANBRIDGE PHARM.DL-00001 (MF1) holds total assets worth €165.39 Million EUR (≈ $193.36 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See MF1 net asset value for net asset value and shareholders' equity analysis.
CANBRIDGE PHARM.DL-00001 - Total Assets Trend (2021–2025)
This chart illustrates how CANBRIDGE PHARM.DL-00001's total assets have evolved over time, based on quarterly financial data.
CANBRIDGE PHARM.DL-00001 - Asset Composition Analysis
Current Asset Composition (December 2025)
CANBRIDGE PHARM.DL-00001's total assets of €165.39 Million consist of 66.6% current assets and 33.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 40.3% |
| Accounts Receivable | €15.12 Million | 9.1% |
| Inventory | €20.57 Million | 12.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €54.71 Million | 33.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how CANBRIDGE PHARM.DL-00001's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MF1 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CANBRIDGE PHARM.DL-00001's current assets represent 66.6% of total assets in 2025, a decrease from 91.0% in 2021.
- Cash Position: Cash and equivalents constituted 40.3% of total assets in 2025, down from 83.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, an increase from 5.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 33.1% of total assets.
CANBRIDGE PHARM.DL-00001 Competitors by Total Assets
Key competitors of CANBRIDGE PHARM.DL-00001 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $285.41 Million |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
|
China | CN¥13.76 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.21 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥772.57 Million |
CANBRIDGE PHARM.DL-00001 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.24 | 0.09 | 0.24 |
| Quick Ratio | 0.20 | 0.08 | 0.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-345.17 Million | €-437.26 Million | €-314.98 Million |
CANBRIDGE PHARM.DL-00001 - Advanced Valuation Insights
This section examines the relationship between CANBRIDGE PHARM.DL-00001's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.92 |
| Latest Market Cap to Assets Ratio | 0.59 |
| Asset Growth Rate (YoY) | 41.6% |
| Total Assets | €165.39 Million |
| Market Capitalization | $98.00 Million USD |
Valuation Analysis
Below Book Valuation: The market values CANBRIDGE PHARM.DL-00001's assets below their book value (0.59x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: CANBRIDGE PHARM.DL-00001's assets grew by 41.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for CANBRIDGE PHARM.DL-00001 (2021–2025)
The table below shows the annual total assets of CANBRIDGE PHARM.DL-00001 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €165.39 Million ≈ $193.36 Million |
+41.59% |
| 2024-12-31 | €116.81 Million ≈ $136.57 Million |
-70.45% |
| 2023-12-31 | €395.36 Million ≈ $462.22 Million |
-43.68% |
| 2022-12-31 | €702.04 Million ≈ $820.76 Million |
-21.34% |
| 2021-12-31 | €892.52 Million ≈ $1.04 Billion |
-- |
About CANBRIDGE PHARM.DL-00001
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatme… Read more